LL-37

LL-37 is a naturally occurring antimicrobial peptide - it is produced by your own immune cells and epithelial tissues as part of the body's first line of defense. In the peptide therapy context, synthetic LL-37 is used to augment this function in people dealing with infections or immune compromise. How it works: LL-37 is an active member of the cathelicidin family of antimicrobial peptides. It disrupts bacterial cell membranes, dismantles biofilms (the protective structures bacteria form to resist antibiotics), and has activity against viruses and fungi as well. Beyond direct antimicrobial activity, it also has immune signaling roles - it helps recruit and activate immune cells at sites of infection. Who tends to use it: People with primary immune support goals, particularly those dealing with stubborn or recurrent infections where biofilm involvement may be a factor. It also carries minor secondary ratings for gut health and recovery. It is often used alongside Thymosin Alpha-1 in more intensive immune protocols. How it is taken: LL-37 is given by subcutaneous (SC) injection. Dosing and frequency are per protocol - both are set at consult because LL-37 is a specialized compound used in specific clinical situations rather than general wellness maintenance. Cycles are kept short and monitored. What to expect: LL-37 is not a general wellness compound. It is used for targeted immune support in situations where its specific antimicrobial and biofilm-disrupting properties are relevant. Safety: The record notes that LL-37 can cause injection-site reactions and is categorized as specialized use. It is classified as emerging evidence. There are no excludeIf flags. Your licensed provider in the PepDepo network will evaluate your specific immune situation and determine whether LL-37 is appropriate, and will set your protocol at consult.